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The impact of the ‘Better Care Better Value’
prescribing policy on the utilisation of
angiotensin-converting enzyme inhibitors
and angiotensin receptor blockers for treating
hypertension in the UK primary care setting:
longitudinal quasi-experimental design
Amanj Baker1,2, Li-Chia Chen1*, Rachel A. Elliott1 and Brian Godman3,4
Abstract
Background: In April/2009, the UK National Health Service initiated four Better Care Better Value (BCBV) prescribing
indicators, one of which encouraged the prescribing of cheaper angiotensin-converting enzyme inhibitors (ACEIs)
instead of expensive angiotensin receptor blockers (ARBs), with 80 % ACEIs/20 % ARBs as a proposed, and achievable
target. The policy was intended to save costs without affecting patient outcomes. However, little is known about the
actual impact of the BCBV indicator on ACEIs/ARBs utilisation and cost-savings. Therefore, this study aimed to evaluate
the impact of BCBV policy on ACEIs/ARBs utilisation and cost-savings, including exploration of regional variations of the
policy’s impact.
Methods: This cross-sectional study used data from the UK Clinical Practice Research Datalink. Segmented time-series
analysis was applied to monthly ACEIs prescription proportion, adjusted number of ACEIs/ARBs prescriptions and costs.
Results: Overall, the proportion of ACEIs prescription decreased during the study period from 71.2 % in April/2006
to 70.7 % in March/2012, with a small but a statistically significant pre-policy reduction in its monthly trend of
0.02 % (p < 0.001). Instantly after its initiation, the policy was associated with a sudden reduction in the proportion
of ACEIs prescription; however, it resulted in a statistically significant increase in the post-policy monthly trend of
ACEIs prescription proportion of 0.013 % (p < 0.001), resulting in an overall post-policy slope of −0.007 %. Despite
this post-policy induced increment, the policy failed to achieve the 80 % target, which resulted in missing a
potential cost-saving opportunity. The pre-policy trend of the adjusted number of ACEIs/ARBs prescriptions was
increasing; however, their trends declined after the policy implementation. The policy affected neither total
ACEIs/ARBs cost nor individual ACEIs or ARBs costs.
Conclusions: ACEIs/ARBs utilisation was not affected by the BCBV policy. The small increase in post-policy ACEIs
prescription proportion was not associated with any savings. This study represents a case study of a failed or
ineffective policy and thus provides key learning lessons for other healthcare authorities. Given the existing
opportunity of potential cost-savings from achieving the 80 % target, specific measures would be needed to
enhance the policy implementation and uptake; however, this must be balanced against other cost-saving policies
in other high-priority areas.
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Background
Hypertension is the leading cause of cardiovascular dis-
ease, resulting in a substantial healthcare burden globally
[1]. The National Institute for Health and Care Excel-
lence (NICE) reported that at least one-quarter of adults
in the UK had primary hypertension in 2011 [2]. Drugs
affecting the renin-angiotensin system (RAS), including
angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs), are among the
most frequently prescribed antihypertensive drugs [3].
Over the past decade, there has been a marked in-
crease in the utilisation and cost of RAS agents, espe-
cially ARBs [4–7]. In the UK, the utilisation of ACEIs/
ARBs increased after the implementation of the Quality
and Outcomes Framework (QoF) in April 2004 and the
publication of revised NICE guidelines for hypertension
management in June 2006 [8]. With GB£277 million
spent on ARBs in England in 2009, ARBs represented
the fourth highest drug cost in the National Health Ser-
vice (NHS England) [9]. Whereas in Scotland, approxi-
mately GB£26.27 million were spent on ARBs, making
them the seventh most expensive drug class [10]. The
NHS Business Services Authority reported a 66 % increase
in the prescription items for ACEIs/ARBs to 13.4 million
items in primary care in England, over a five-year period
from June/2004 to June/2009 [11]. Furthermore, the Pre-
scription Cost Analysis (PCA) of England-2011, issued by
the Health and Social Care Information Centre of the UK,
considered ACEIs/ARBs as being the second most com-
monly prescribed drug class in English primary care, ac-
counting for 6 % of all prescribed drugs [12].
ACEIs and ARBs are considered to have equal efficacy
in hypertension control and cardiovascular disease pre-
vention [3, 13], except that ACEIs are more likely to
cause a dry cough (2–10 %) [3] than ARBs. However,
only 2–3 % of patients actually stopped ACEIs in clinical
trials due to dry cough [13, 14]. Therefore, efficient pre-
scribing of RAS agents, i.e., prescribing cheaper generic
ACEIs instead of more expensive patent protected ARBs,
is considered an important cost-saving strategy.
The efficient prescribing of RAS agents has been
under intensive scrutiny in many European countries
and regions, ex. Austria, Croatia, Serbia, Scotland, Spain,
Sweden, and the Republic of Srpska, with multiple initia-
tives targeting ACEIs/ARBs prescribing to enhance their
efficient use, including prescriber education, prescribing
targets and restrictions, and financial incentives [15–17].
In the UK, the NHS Institute for Innovation and Im-
provement released four Better Care Better Value
(BCBV) prescribing indicators in April 2009 [18], one of
which targeted the ACEIs prescribed as a proportion of
RAS agents prescribed overall. This built on initiatives
via NICE, National Prescribing Centre (NPC) and Pri-
mary Care Trusts (PCTs) to encourage the prescribing
of generic ACEIs first line if a RAS agent was being con-
sidered, with ARBs reserved for patients intolerant to
ACEIs [19–21].
The BCBV policy was passively disseminated through
emails to people who are responsible for prescribing and
medicine management within NHS organisations, dis-
cussion in workshops and/or via emails to individual
GPs informing them about the establishment of the pol-
icy with a link to the full policy’s details. However, the
policy was neither linked to any central financial incen-
tives, legislation enforcement nor any other strategies to
increase its uptake, although there could have been local
PCT initiatives. Although a clear target for ACEIs pre-
scription proportion was not specified, a proportion of
at least 80 % ACEIs had been proposed by the NICE
based on experts’ opinions [2] and was considered as an
achievable target [22]. The UK Office of Fair Trading
(OFT) [23] suggested a higher target of 95 % ACEIs
based on the fact that only 2–3 % of patients in clinical
trials actually stopped ACEIs due to dry cough [24, 25]
and the OFT panel opinion that only about 5 % of pa-
tients would stop ACEIs therapy due to dry cough [23].
However, the 80 % target seems more likely to be ac-
ceptable as it would leave room for preserving physi-
cians’ and patients’ choice and autonomy. For the BCBV
indicator to achieve its goal, this required general practi-
tioners (GPs) to initiate new patients on ACEIs and
switch existing ARBs users to ACEIs when appropriate.
In the UK, GPs act as a gatekeeper to the NHS and
under the new NHS structure of Clinical Commissioning
Groups (CCGs), they are in charge of arranging the
health services that meet the local needs through work-
ing with patients and health and social care partners.
Consequently, GPs have greater freedom and leadership
roles [26].
The importance of the appropriate prescribing of RAS
drugs in saving the NHS money has been further
emphasised by the Quality, Innovation, Productivity and
Prevention (QIPP) programme established in 2010, which
aimed to enhance the value derived from NHS money
while maintaining or improving quality of provided care
through the optimisation of medicines use [27]. This em-
phasis has been performed by identifying and including
RAS drugs as one of the key topic areas, where maintain-
ing or improving quality while improving the value of
money is a potential opportunity, in the QIPP key
therapeutic topics document, which summarises the
evidence on the topics identified to support the QIPP
programme [28].
The BCBV policy intended to improve the efficient
use of healthcare resources and quality of care within
NHS organisations, and compares the ACEIs/ARBs util-
isation across organisations [29], which was shown to
vary across the UK regions [22, 30]. The policy was
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expected to achieve a marked cost-saving to the NHS,
which can be invested to support other areas within
NHS such as funding new premium priced innovative
medicines. Within the NHS, medicines represent one of
the greatest non-salary areas of expenditure and have
been scrutinised intensively for many years [31].
Inappropriate spending on prescribed medicines by
GPs in 1994 was estimated to cost about GB£300 million
a year [32]. Even more than a decade later, the National
Audit Office (NAO) report concerning prescribing costs
in primary care in the UK in 2007 [33] found that a po-
tential cost saving of more than GB£200 million a year
could be achieved, without compromising the quality of
care, through efficient prescribing in four therapeutic
drug classes, including RAS drugs. In fact, this estimated
cost-saving figure was the essence behind initiating the
BCBV prescribing indicator.
Furthermore, the National Prescribing Centre of England
estimated a potential annual future saving ranging from
GB£68 million to GB£149 million if the ACEIs prescrip-
tion proportion increased from 70 % in 2009 to 80 % and
90 %, respectively [22]. However, currently it is also recog-
nised that this potential saving could have been reduced
by the concurrent introduction of several relatively lower
cost generic ARBs (losartan, candesartan, irbesartan, val-
sartan). Apart from the NAO estimated cost saving figures
from efficient prescribing of RAS drugs, little is known
about the actual impact of BCBV prescribing indicator on
ACEIs/ARBs utilisation and cost-savings.
Aim and objectives
This study aimed to evaluate the impact of the BCBV
prescribing policy on ACEIs/ARBs utilisation and cost-
saving for treating hypertension in the UK primary care
setting and to explore potential regional variations of the
policy’s impact.
Methods
Study design and data sources
This cross-sectional study adopted a natural quasi-
experimental design [34] and applied a segmented time-
series analysis [35] to investigate the impact of BCBV
prescribing policy on ACEIs/ARBs utilisation, using data
from the UK Clinical Practice Research Datalink (CPRD)
database [36] from April 2006 to March 2012. This
study protocol was approved by the Independent Scien-
tific Advisory Committee for study quality standard and
access of CPRD database (protocol number 13_150).
The CPRD contains anonymised longitudinal clinical
data collected from GPs’ daily records in primary care. It
is broadly representative of the UK population in terms
of patient and practice characteristics [37] and covers
about 8.5 % of the UK population. In March 2015, it
contained longitudinal clinical records of more than 13.7
million patients and 5.4 million active patients from 685
primary care practices across the UK [38].
CPRD is a prescribing dataset containing detailed in-
formation about prescriptions issued by GPs. Drug pre-
scription information is well recorded and can be linked
to an individual patient's clinical and medical informa-
tion. Therefore, CPRD is an optimal data source for ana-
lysing drug utilisation in the UK primary care, where
there is currently no means to collect patient identity
data across the whole population, particularly in evaluat-
ing the impact of BCBV indicator as it provides compre-
hensive information about GPs’ prescribing habits which
the policy aimed to make more efficient.
Despite all those merits, CPRD data were available up
to March 2012 at the time of conducting this study.
Consequently, data from the Prescription Cost Analysis
(PCA) of England [39] was used to estimate the potential
up to date national cost-saving impact of this BCBV pol-
icy. Furthermore, to ensure that CPRD data reflected the
national data, data from the Health and Social Care In-
formation Centre (HSCIC) [40] was used to validate the
study results. Both PCA and HSCIC datasets contain ag-
gregate level information about all the prescriptions that
dispensed in the community in England; however, they
lack clinical information such as the indication of use as
well as does not allow to link prescriptions to an individ-
ual patient.
This study included all antihypertensive prescriptions
issued for adults (≥18 years old) with primary hyperten-
sion from April 2006 to March 2012. As the policy im-
plementation involves both actions of starting incident
patients on ACEIs and switching prevalent ARBs users
to ACEIs, both incident and prevalent patients were in-
cluded to obtain a full picture about the policy impact.
Patients with primary hypertension and their antihyper-
tensive prescriptions were identified using related diag-
nostic Read codes and product codes, respectively.
Utilisation measures
The proportion of ACEIs prescriptions was calculated
monthly as the primary utilisation measure, and was
stratified by the 13 UK regions because we expected po-
tential variations in the policy adoption in various regions
due to the lack of central incentives to implement the
policy. The number of ACEIs/ARBs prescriptions and
ACEIs/ARBs prescription costs were repeatedly measured
for each month. The total number of patients with pri-
mary hypertension and total number of antihypertensive
prescriptions were also calculated and stratified by the 13
regions. Both single strength ACEIs/ARBs and fixed-dose
combinations (FDCs) of ACEIs/ARBs with other antihy-
pertensive drugs were included in the analysis, although
previous UK studies have shown that FDCs only accounted
for less than 2 % of total RAS drugs [10, 15].
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The number of prescriptions was used as the utilisa-
tion measure for ACEIs and ARBs as opposed to the
internationally recognised defined daily doses [41] be-
cause the number of prescriptions has been the utilisa-
tion metric used by UK NHS professionals to calculate
BCBV indicators [42]. To ensure that the observed
changes in the number of prescriptions were not an
artefact of monthly alteration in both number of active
patients registered in CPRD and number of patients with
hypertension, the number of prescriptions was trans-
formed and presented as adjusted monthly number of
prescriptions which was derived from dividing the abso-
lute number of prescribed prescriptions by the prevalence
of hypertension in the same month, i.e., the resulted num-
ber, therefore represents the number of prescriptions per
one-percent hypertension prevalence. Monthly hyperten-
sion prevalence was calculated by dividing the number of
hypertensive patients by the number of active patients reg-
istered in CPRD in the same month.
Prescription costs were calculated by multiplying pre-
scribed quantities of ACEIs and ARBs by unit prices ob-
tained from the British National Formulary (BNF),
March 2012 [43]. The 2012 unit price was used rather
than historical prices in order to estimate the change in
drug expenditure from the NHS perspective, whilst con-
trolling for inflation [44], as well as because March 2012
was the last available date for CPRD data at the time of
the study.
Prediction of the potential cost saving of BCBV policy
The potential cost-saving in March 2012, had the 80 %
ACEIs target been achieved was estimated, which was
then applied to the national ACEIs/ARBs costing figure,
obtained from England Prescription Cost Analysis (PCA)
March 2012 data [39], to estimate the potential cost-
saving on a national level.
Firstly, the predicted number of ACEIs prescriptions
was calculated by multiplying the actual total number of
ACEIs/ARBs prescriptions in March 2012 by 80 %, which
was afterwards subtracted from actual total ACEIs/ARBs
prescriptions to calculate the predicted number of ARBs
prescription. Secondly, the predicted number of ACEIs
and ARBs prescriptions was multiplied by the mean cost
of ACEIs and ARBs per prescription in March 2012, re-
spectively, to calculate the predicted cost of ACEIs and
ARBs prescriptions. The mean cost of single ACEIs and
ARBs prescription were estimated by dividing the actual
total cost of ACEIs and ARBs by their actual number of
prescriptions in March 2012, respectively. Finally, the po-
tential cost saving was calculated by subtracting total ac-
tual ACEIs/ARBs cost in March 2012 from the total
predicated ACEIs/ARBs cost.
Data from PCA of England in June 2014 [39], the most
up-to-date data available at the date of submission,
which contains the number of dispensed antihyperten-
sive drug prescriptions and their costs, were also ana-
lysed to estimate the impact of the availability of low
cost generic ARBs on the potential cost-saving of BCBV
policy if the 80 % target had been achieved in June 2014
in England. The potential cost-saving was estimated
using the same procedures described above, but applying
the 2014 costs.
Data analysis
Segmented regression of the interrupted time series [35]
was used to analyse the time-series of monthly utilisa-
tion measures from April 2006 to March 2012. The ana-
lysis of ACEIs prescription proportion was stratified by
the 13 UK regions. As the BCBV indicator targeted the
proportion of ACEIs prescribed as a % of total RAS pre-
scriptions, prescriptions were used as the unit of analysis
and thus prescription level analysis was performed.
The trends of utilisation (β1) in the pre-intervention
period, and any changes in the levels (β2) and trends of
utilisation (β3) following the intervention were assessed
and presented [35]. To control for potential confounders
[34], the fitted models for all utilisation measures were
adjusted for the launch of generic perindopril in October
2007 and the launch of generic losartan in July 2010.
Data analysis was performed using STATA 12 (Stata-
Corp, Texas, USA).
The following segmented regression model was fitted
for each individual study outcome measure:
Yt ¼ β0þ β1
time þ β2
BCBV intervention
þ β3
time after BCBV intervention
þ β4
launch of generic losartan
þ β5
time after launch of generic losartan
þ β6
launch of generic perindopril
þ β7
time after launch of generic perindopril þ et
Yt is the monthly outcome measure. Time is a continu-
ous variable referring to time, in months, from the start of
the observation period, range from 1 to 72 from the start
to end of the study period. BCBV intervention is a binary
variable, takes the value of zero and one for the time be-
fore and after intervention implementation, respectively,
i.e., zero from the start till month 36, then one afterward.
Time after BCBV intervention is a continuous variable
counting the number of months after the BCBV interven-
tion at time t, coded 0 before the intervention and (time-
36) after the intervention. Launch of generic losartan is a
binary variable, takes the value of zero and one for the
time before and after intervention implementation, re-
spectively, i.e., zero from the start till month 51, then one
afterward. Time after launch of generic losartan is a con-
tinuous variable counting the number of months after the
launch of generic losartan at time t, coded 0 before the
intervention and (time-51) after the intervention. Launch
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of generic perindopril is a binary variable, takes the value
of zero and one for time before and after intervention im-
plementation, respectively, i.e., zero from the start till
month 18, then one afterward. Time after launch of gen-
eric perindopril is a continuous variable counting the
number of months after the launch of generic perindopril
at time t, coded 0 before the intervention and (time-18)
after the intervention. et is an error term at the time t
which describes the random variability in outcome not ex-
plained by the model.
To obtain unbiased estimates for the intervention ef-
fect, the final fitted models were checked for autocorrel-
ation in the residuals using an autocorrelation function
graph [35] and the Portmanteau test [45], and any auto-
correlation was adjusted for using Prais-Winsten regres-
sion and an auto-regressive integrated moving-average
model [34]. The regression coefficients with 95 % confi-
dence intervals were presented for the most parsimonious
model by excluding non-significant variables (p > 0.05)
using the stepwise backward elimination method [35].
However, all the parameter estimates with their 95 % con-
fidence intervals were also presented as additional files.
Since the baseline ACEIs prescription proportion before
the implementation of BCBV policy differed in various re-
gions [22], the results of ACEIs prescription proportions
analysis for the 13 UK regions were grouped into high
(>74 %), intermediate (65 %-74 %) and low levels (<65 %)
groups, based on the ACEIs prescription proportion in
April 2006.
Ideally, to separate the effect of BCBV policy from
other policies that might have been established at the
same time, the impact of BCBV policy on ACEIs/ARBs
utilisation should be compared to those in a BCBV
policy-free group (reference group). However, it was not
possible to identify a BCBV policy-free group as the pol-
icy was implemented nationally. As an alternative, the
utilisation of the other four major antihypertensive drug
classes, i.e., diuretics, calcium-channel blockers (CCBs),
beta-blockers (BBs), and ‘Others’ (including vasodilators,
centrally acting drugs, alpha-blockers), that should not
be affected by this specific policy were used as reference
(policy-free) groups [34, 35]. With this approach, separate
models were re-specified with the utilisation of the other
four antihypertensive drug classes as the dependent vari-
able in each instance.
To validate the study results, the quarterly trends in
the number of ACEIs/ARBs prescriptions and other
antihypertensive drug classes were also compared with
the quarterly England dispensing data, which contains
the number of antihypertensive drugs prescriptions
dispensed in the primary care setting in England for
treatment of all conditions, and obtained directly from
the Health and Social Care Information Centre
(HSCIC) [40].
Results
Adjusted monthly number of antihypertensive
prescriptions
Overall, 44,408,931 antihypertensive prescriptions were
issued to 617,334 patients with primary hypertension
during the study period. On average, each patient had
one antihypertensive drug prescription per month dur-
ing the six-year study period, with a median duration of
28 days for the individual antihypertensive drug classes,
which is consistent with the normal practice of prescrib-
ing one-month supply in the UK. ACEIs were the most
frequently prescribed antihypertensive drugs with 11,222,597
(25.3 %) prescriptions, followed by diuretics (n= 10,297,565,
23.3 %), CCBs (n = 9,245,498, 20.8 %), BBs (n = 6,873,068,
15.5 %), ARBs (n = 4,610,122, 10.4 %), and “Others” (n =
2,160,081, 4.9 %). In April 2006, diuretics were the most
frequently prescribed antihypertensive class (Fig. 1). In
total, the adjusted number of ACEIs, ARBs, and CCBs
prescriptions showed an absolute increase during the
study period of 4.8 %, 2.2 %, and 3.9 %, respectively. Con-
sequently, ACEIs became the leading prescribed antihy-
pertensive drug category by the end of the study period.
Prior to the BCBV policy, there was a significant increase
in baseline trend in the adjusted number of prescriptions of
ACEIs (β1: 135.7, p < 0.001), ARBs (β1: 65.9 %, p < 0.001),
CCBs (β1: 90.4, p < 0.001) (Table 1), but significant re-
duction in diuretics (β1: −55.4, p < 0.001), BBs (β1:
−102.7, p < 0.001) and “Others” (β1: −3.0, p < 0.001). Al-
though the implementation of the BCBV policy had no
significant effect on the level of the adjusted number of
prescriptions (β2) for all drug classes, there was a sig-
nificant reduction in the trend of the adjusted number
of prescriptions (β3) for all drug classes thereafter, ex-
cept for diuretics (Table 1). All the observed changes
were small in magnitude, albeit statistically significant.
All the parameter estimates were presented in Add-
itional file 1.
ACEIs prescription proportion
The proportion of monthly ACEIs prescription was 71.2 %
in April 2006, but had declined to 70.7 % in March 2012.
There was a significant reduction in the monthly trend of
ACEIs prescription proportion (β1: −0.02 %, p < 0.001) be-
fore the implementation of BCBV policy, and the level of
ACEIs prescription proportion further reduced when the
policy was implemented (β2: −0.3 %, p < 0.001). However,
the policy resulted in a sustained significant increase in the
monthly ACEIs prescription trend (β3: 0.013 %, p < 0.001)
thereafter (Table 1), i.e., the policy reversed the existing
declining monthly trend by 0.013 %, so that the slope of
the post-policy line (β1+ β3) was declining by 0.007 %
compared with the pre-policy declining rate of 0.02 %. Al-
though all the observed changes were very minute in mag-
nitude, they were statistically significant.
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Seven of the 13 regions’ baseline ACEIs prescription
proportion ranged from 65 to 74 % of total RAS pre-
scriptions (Table 2), while four and two regions’ baseline
proportions were in the high and low level, respectively.
The regional difference between the highest (80.8 % in
the North East) and lowest (60.3 % in Northern Ireland)
ACEIs prescription proportion was 20.5 %. However, the
marginal difference between the highest and the lowest
ACEIs prescription proportion declined over time from
20.5 % in April 2006 to 12 % in March 2012, i.e., the
highest proportion was in East Midlands (75.8 %) while
the lowest was in South East Coast (63.8 %). The results
from the regression parsimonious models (Table 3, Add-
itional file 2) indicated a wide variation in the policy
impact on the ACEIs prescription proportion across
various regions. Although there was no clear pattern of
the policy impact, the policy generally seemed to have
least influence in regions with the highest and lowest
baseline ACEIs prescription proportions.
Monthly ACEIs/ARBs prescriptions’ cost
Overall, total ACEIs/ARBs cost decreased by only 0.3 %
during the study period, from GB£1,182,656 in April
2006 to GB£1,178,674 in March 2012. However, there
was a 26.1 % reduction in monthly ACEIs cost from GB
£453,303 in April 2006 to GB£334,934 in March 2012,
whereas the monthly ARBs cost increased by 15.7 %,
Fig. 1 Adjusted monthly number of prescriptions for the six antihypertensive drug classes. a time point when generic perindopril became
available (October 2007); b time point when BCBV policy was implemented April 2009); c time point when generic losartan launched (July 2010);
ACEIs: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin receptor blockers; CCBs: Calcium channel blockers; BBs: Beta-blockers
Table 1 Segmented regression analysis on monthly adjusted number of prescription of the six antihypertensive drug classes
Variables β1
(a) β2
(b) β3
(c) β4
(d) β5
(e) β6
(f) β7
(g)
ACEIs prescription proportion (%) −0.02 (−0.2, −0.01) −0.30 (−0.44, −0.16) 0.013 (0.007, 0.02) — — — —
Adjusted number of prescriptions
ACEIs 135.7 (117.8, 153.6) — −149.9 (−181.4, −118.4) — — — —
ARBs 65.9 (58.7, 72.0) — −67.2 (−79.8, −54.6) — — — —
Diuretics −55.4 (−61.9, −48.9) — — — — — —
CCBs 90.4 (77.0, 103.9) — −77.4 (−101.1, −53.8) — — — —
BBs −102.7 (−119.0, −86.5) — −75.3 (−98.3, −52.4) — — — —
“Others” −3.0 (−4.9, −1.0) — −15.6 (−21.1, −10.1) — — — —
Regression coefficients (95 % confidence intervals) for the final model (the most parsimonious models); (a)baseline trend; (b)level change following BCBV policy;
(c)trend change following BCBV policy; (d)level change following generic losartan availability; (e)trend change following generic losartan availability; (f)level change
following generic perindopril availability; (g)trend change following generic perindopril availability; −–: indicates insignificant estimates at 0.05 level, after stepwise
backward elimination; ACEIs: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin receptor blockers; CCBs: Calcium channel blockers; BBs: Beta-blocker
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from GB£729,353 to GB£843,740 (Fig. 2). The BCBV
policy neither affected the level (β2) nor the trend
(β3) of total ACEIs and ARBs, ACEIs or ARBs costs
following its implementation in April 2009 (Table 4,
Additional file 3).
Prediction of the potential cost saving of BCBV policy
A potential cost-saving of 23.9 % (GB£227,593) of the
total ACEIs/ARBs costs would have been made in March
2012 if the ACEIs prescriptions’ proportion of 80 % of
total RAS had been achieved, instead of the current
Table 2 Number of patients, antihypertensive prescriptions and baseline ACEIs prescription proportion in the 13 UK regions
Regions Baseline ACEIs prescription
proportion (%)
ACEIs prescription proportion (%)
at the end of the study
Total number of
prescriptions
Total number of
patients
High baseline ACEIs prescription proportion (>74 %)
North East 80.8 74.2 1,143,760 13,319
South East 74.7 71.6 3,865,373 53,299
Wales 74.4 74.1 6,185,924 63,467
East Midlands 74.3 75.8 1,364,324 22,370
Intermediate baselineACEIs prescription proportion (65 %-74 %)
Yorkshire and the
Humber
73.5 73.6 1,554,143 20,968
East of England 72.5 72.1 3,505,910 52,733
South Central 71.7 70.9 5,030,800 69,175
Scotland 72.2 70.8 3,760,187 62,610
West Midlands 69.5 68.5 3,764,019 52,920
North West 69.2 70.8 6,279,440 80,575
London 69.1 70.9 3,401,591 57,108
Low baseline ACEIs prescription proportion (<65 %)
South East Coast 63.6 63.8 3,698,109 52,221
Northern Ireland 60.3 65.5 801,164 15,256
ACEIs Angiotensin converting enzyme inhibitors
Table 3 Segmented regression analysis on the monthly ACEIs prescription proportion in the 13 UK regions
Regions β1
(a) β2
(b) β3
(c) β4
(d) β5
(e) β6
(f) β7
(g)
High baseline ACEIs prescription proportion (>74 %)
North East −0.12 (−0.13, −0.11) — — — 0.04 (0.02, 0.06) — —
South East −0.06 (−0.70, −0.05) −0.31 (−0.7, −0.07) 0.02 (0.01, 0.04) — — — —
Wales — — — — — — —
East Midlands −0.03 (−0.04, −0.16) — — −0.64 (−1.1, −0.20) 0.16 (0.13, 0.19) — —
Intermediate baseline ACEIs prescription proportion (65 %-74 %)
Yorkshire and the Humber −0.08 (−0.09, −0.06) — 0.20 (0.14, 0.24) −1.80 (−0.26,-0.9) — — —
East of England −0.08 (−0.70, −0.05) −0.40 (−0.7, −0.05) 0.02 (0.04, 0.03) — — — —
South Central −0.01 (−0.2, −0.002) −0.60 (−0.9, −0.40) — −0.47 (−0.7, −0.20) — — —
Scotland — — 0.06 (0.04, 0.08) −0.49 (−0.80, −0.10) — — —
West Midlands — — −0.03 (−0.04, −0.02) — — — —
North West 0.01 (0.02, 0.018) −0.57 (−0.8, −0.33) 0.04 (0.03, 0.05) — — — —
London — 0.40 (0.20, 0.60) — — 0.04 (0.03, 0.05) — —
Low baseline ACEIs prescription proportion (<65 %)
South East Coast 0.013 (0.004, 0.02) −0.42 (−0.7, −0.20) −0.02 (−0.03,-0.002) — — — —
Northern Ireland 0.06 (0.05, 0.08) — — — 0.06 (0.02, 0.09) — —
Regression coefficients (95 % confidence intervals) for the final model (the most parsimonious models); (a)baseline trend; (b)level change following BCBV policy;
(c)trend change following BCBV policy; (d)level change following generic losartan availability; (e)trend change following generic losartan availability; (f)level change
following generic perindopril availability; (g)trend change following generic perindopril availability; −–: indicates insignificant estimates at 0.05 level, after stepwise
backward elimination; ACEIs: Angiotensin converting enzyme inhibitors
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value of 70.7 %, based on the total ACEIs/ARBs costs of
GB£1,178,674 and the number of ACEIs prescriptions of
174,153 and ARBs prescriptions of 72,240 in March
2012. Applying this estimated 23.9 % cost-saving figure
to England’s total ACEIs/ARBs spending in March 2012
of GB£2,220,548,343 would yield an equivalent cost-
saving figure of GB£530,711,054.
The analysis of June 2014 PCA data of England indi-
cated that if the 80 % BCBV target had been achieved in
June 2014, instead of the current June 2014 value of
70.3 %, a potential cost-saving of GB£92,688,486 (8.7 %)
of the total ACEIs/ARBs cost (GB£1.06 billion) would
have been made in June 2014 from enhancing the pre-
scribing efficiency of ACEIs and ARBs.
Comparison with the national figures
Results from the HSCIC quarterly dispensing dataset
analyses (Table 5, Additional file 4) showed a significant
declining trend in the ACEIs prescriptions’ proportion
prior to the BCBV policy implementation (β1: -0.09 %, p
< 0.001). Although the policy had no instant impact on
the level (β2) of ACEIs prescriptions’ proportion, it re-
sulted in a significant increase in the trend of the ACEI
prescriptions’ proportion thereafter (β3: 0.1 %, p < 0.001).
The results from the analysis of quarterly national dis-
pensing data were consistent with that obtained from the
CPRD dataset analysis (Table 5), which showed a signifi-
cant decrease in the trend of ACEIs prescriptions propor-
tion prior to the policy implementation (β1: −0.04 %, p <
0.001), no instant policy impact (β2), but a significant in-
crease in the post-policy trend (β3: 0.04 %, p < 0.001).
The quarterly number of prescriptions of the six anti-
hypertensive drug classes from the HSCIC dataset
showed a significant pre-policy increasing trend (β1) in
all antihypertensive drug classes, except for diuretics
(Fig. 3). The policy implementation did not instantly
Fig. 2 Monthly cost of total ACEIs/ARBs, ACEIs and ARBs from April 2006 to March 2012. a time point when generic perindopril became available
(October 2007); b: time point when BCBV policy was implemented (April 2009); c: time point when generic losartan launched (July 2010); ACEIs:
Angiotensin converting enzyme inhibitors; ARBs: Angiotensin receptor blockers
Table 4 Segmented regression analysis on the monthly cost of ACEIs/ARBs, ACEIs and ARBs
Variables β1
(a) β2
(b) β3
(c) β4
(d) β5
(e) β6
(f) β7
(g)
ACEIs/ARBs 22072 (15546,28599) — — −287538
(−368885,-206192)
−15970 (−21775,-10164) −266656 (−349379,-183932) −15019 (−22054,-7983)
ACEIs 6228.8 (4372, 8086) — — — — −286941 (−308447,-265435) −6094 (−7971,-4217)
ARBs 17030 (13449, 20611) — — −298044
(−357163, −238924)
−15548 (−19712,-11384) — −9839 (−14560,-5118)
Regression coefficients (95 % confidence intervals) for the final model (the most parsimonious models); (a) baseline trend; (b) level change following BCBV policy; (c)
trend change following BCBV policy; (d) level change following generic losartan availability; (e) trend change following generic losartan availability; (f) level change
following generic perindopril availability; (g) trend change following generic perindopril availability; −–: indicates insignificant estimates at 0.05 level, after stepwise
backward elimination; ACEIs: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin receptor blockers
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Table 5 Segmented regression analysis on the quarterly number of antihypertensive prescriptions and ACEIs prescription proportion
Variables β1
(a) β2
(b) β3
(c)
Health and Social Care Information Centre (HSCIC) data
ACEIs prescription proportion (%) −0.09 (−0.10, −0.70) — 0.10 (0.09, 0.13)
ACEIs 179422.8 (155964.2, 202881.5) — −88326.8 (−128278.1,-48375.6)
ARBs 87446.1 (77192.5, 97699.7) — −52359.4 (−69821.8, −34897.1)
Diuretics — — —
CCBs 121943.8 (106805.8, 137081.8) — −40240.7 (−66021.5, 14459.9)
BBs 22331.1 (2253.2, 42409.0) — 61787.6 (27593.9, 95983.2)
“Others” 15605.9 (12056.8, 19154.0) — −7041.9 (−13085.4, 998.4)
Clinical Practice Research Datalink (CPRD) data
ACEIs prescription proportion (%) −0.04 (−0.6, −0.02) — 0.04 (0.01, 0.07)
ACEIs 15862.3 (14300.5, 17427.0) — −14529.7 (−17189.5, −11869.9)
ARBs 6993.5 (6377.5, 7609.4) — −6167.7 (−7216.6, −5118.6)
Diuretics 6414.9 (5325.2, 7504.5) — −8312.0 (−10167.6, −6456.2)
CCBs 11960.5 (10917.0, 13003.9) — −9576.0 (−11353.1, −7798.9)
BBs 1681.0 (948.6, 2413.4) — −1689.5 (−2936.7, −442.2)
“Others” 1765.0 (1572.7, 2002.3) — −1924.8 (−2328.9, −1520.6)
Regression coefficients (95 % confidence intervals) for the final model (the most parsimonious models); (a):baseline trend; (b):level change following BCBV policy;
(c):trend change following BCBV policy; −– : Indicates insignificant estimates at 0.05 level, after stepwise backward elimination; ACEIs: Angiotensin converting
enzyme inhibitors; ARBs: Angiotensin receptor blockers; CCBs: Calcium channel blockers; BBs: Beta-blockers
Fig. 3 Quarterly number of antihypertensive prescriptions comparing HSCIC and CPRD dataset. b: time point when BCBV policy was
implemented (April 2009); HSCIC: Health and Social Care Information Centre dataset, which contains whole dispensing data for all indications in
England; CPRD: Clinical Practice Research Datalink, which contains prescription data for essential hypertension patients who registered in the
practices included in CPRD; ACEIs: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin receptor blockers; CCBs: Calcium channel
blockers; BBs: Beta-blocker
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impact on the level (β2) of the number of prescriptions
for all antihypertensive classes; but significantly reduced
the trend for almost all classes (β3) (Table 5). These re-
sults were comparable with the results derived from the
CPRD database analysis (Table 5).
The results presented in Table 5 regarding CPRD
could appear different from the results in Table 1 due to
the difference in the level of analysed data since in the
latter data were analysed at a monthly level; whereas in
the former data were analysed at a quarterly level. Quar-
terly level analysis was performed on CPRD data in
order to compare the results with the national data,
which was only available as quarterly level data. In fact,
the comparability of the results between the two data
sets suggests the representativeness and generalisability
of CPRD findings to the national UK population.
Discussion
Main findings
This study found that ACEIs prescribing as a proportion
of RAS medicines was decreasing during the study
period, and BCBV policy moderated the extent of this
decreasing trend after its implementation as it was asso-
ciated with a sustained monthly increase in ACEIs pre-
scription proportion. However, although the increase
was statistically significant, it was very small in magni-
tude, and it could be of no policy/clinical significance,
especially the policy failed to achieve the expected target
of 80 % ACEIs. We acknowledge though that the impact
of BCBV policy varied among the 13 UK regions. The
reduction in post-policy adjusted number of prescrip-
tions for ACEIs/ARBs and the other antihypertensive
classes (reference groups), imply that factors other than
the BCBV policy could have contributed to the reduc-
tion in the number of prescriptions.
The policy had neither immediate nor sustained effect
on total ACEIs/ARBs costs, ACEIs or ARBs costs indi-
vidually. The results indicated that failure to achieve the
80 % BCBV target in March 2012 had led to miss poten-
tial cost-saving of 23.9 % of total ACEIs/ARBs cost. Im-
portantly, although the potential cost-saving of efficient
ACEIs/ARBs prescribing was moderated by the availabil-
ity of generic ARBs, the analysis of June 2014 PCA data
indicated that the failure of achieving the 80 % ACEIs
target in June 2014 resulted in losing (8.7 %, GB
£92,688,486) a potential cost-savings opportunity in the
total ACEIs/ARBs costs (GB£1.06 billion). This potential
opportunity observed in June 2014 was found despite
four years after the availability of generic ARBs starting
with generic losartan.
Implementation of the BCBV policy
Generally, inappropriate policy measures and/or inad-
equate policy implementation are the two common
causes underpinning any policy failure [46]. Since the
BCBV measure of 80 % ACEIs prescription proportion
was considered an achievable target [2], the lack of full
implementation could be the main cause of the policy
failure, especially the BCBV policy was not linked to any
national financial incentives or legislation enforcements;
consequently, general practitioners (GPs) may have been
reluctant and/or less motivated to uptake the policy.
However, this needs further investigation to provide
learning lessons for future policies. The observed re-
gional variation of the policy’s impact could reflect the
possible variation of policy implementation as different
regions may have been implementing various strategies
to promote the policy uptake, and implementation bal-
anced against other identified priorities.
This is consistent with the well-known fact that mul-
tiple measures are typically required to alter prescribing
patterns effectively, given the complex nature of pre-
scribing, and that a single measure could fail to achieve
any significant change in prescribing behaviour [47–51].
It has been shown in other European countries that mul-
tiple intensive demand-side measures, e.g., combination
of prescribing guidance, prescribing targets, financial in-
centives, and/or prescribing restrictions, are usually re-
quired to improve prescribing efficiency, including
limiting the prescribing of patented ARBs vs. generic
ACEIs [15, 17, 52, 53], and that countries with few mea-
sures, e.g., Portugal, failed to improve ARBs prescribing
efficiency [15, 47].
Overall, the failure of linking BCBV policy with any
national financial incentive or enforcement, as in QoF
targets, or alternatively any universal PCT formulary and
prescribing incentive scheme, may be the main contribu-
tor to the apparent poor implementation of the policy
and hence its ineffectiveness. Consequently, specific
measures will be required to enhance the implementa-
tion and uptake of this BCBV indicator, such as linking
the target with financial incentives, and/or active switch-
ing programme, building on the previous experience
with statins and proton pump inhibitors [54–57]. How-
ever, the active switching may disturb the patient-
physician relationship and detriment therapeutic adher-
ence; hence the policy should focus more on initiating
eligible patient with ACEIs.
Instigating prescribing indicator for ACEIs vs. ARBs in
the UK several years after the availability of ARBs was
rather unique. Other countries, such as Sweden, insti-
gated prescribing restrictions relegating ARBs to second
line in 2008 several years after the availability of ARBs–
so offers some comparisons. However, in Sweden, this
was a prescribing restriction rather than a prescribing
target; so greater impact in practice compared to no
additional measures associated with BCBV since the pre-
scribing restriction resulted in a 24 % reduction in the
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number of patients prescribed ARBs in the first four
months after prescribing restrictions were introduced
whilst increasing for ACEIs and CCBs, by 14 % and
12 %, respectively. The proportion initiated on ARBs
prescribed an ACEI within 24 months prior to an ARB
increased from 51 to 67 % [58].
Other reasons for the policy failure
It could be argued that the observed lack of policy effect-
iveness merely reflects the fact that the encouragement of
prescribing low cost generic ACEIs against patented ARBs
was the subject of health authorities (HAs) in the UK some
time before the launch of this BCBV policy, as seen in
Scotland [59]. In Scotland, multiple measures were imple-
mented between 2001 and 2007, including prescribing tar-
gets and financial incentives, and they resulted in a similar
influence on limiting the prescribing of ARBs as those pol-
icies of prescribing restrictions coupled with financial in-
centives were implemented in Austria and Croatia [57].
Similarly, among PCTs in other parts of the UK, lots of
local guidelines have been built based on NICE and NPC
guidance as well as PCT activities [16–18]. Consequently,
by the time this BCBV was launched in 2009, GPs and
pharmaceutical advisers had turned their attention to
other areas, hence, the limited impact of BCBV policy. A
similar scenario was observed in Sweden, where the recent
implementation of prescribing restrictions for patented
statins had limited impact because these were introduced
some six to seven years after pharmaceutical advisers and
others working for the regions had been pushing for the
increased prescribing of generic statins [60].
Although the previous HA and PCT activities could
have played an important role in limiting ARBs utilisa-
tion, the declining ACEIs prescription proportion trend
in the pre-policy period combined with its value being
below the proposed target of 80 % should theoretically
enhance the effectiveness of BCBV policy rather than
impede its efficacy since there were opportunities for
further improving the proportion of ACEIs prescriptions.
Therefore, the activities of the HAs and PCTs in the UK
in the previous years are unlikely to fully explain the lack
of effectiveness of this BCBV indicator; although it was
not possible to elicit what individual practice had actu-
ally done in terms of local initiatives to enhance ACEIs/
ARBs prescribing efficiency following the introduction of
this BCBV. We acknowledge this is a limitation of the
paper. Furthermore, other factors such as GP’s prescrib-
ing preference and clinical issues related to switching
from ARBs to ACEIs, and patients’ choice could not be
ruled out as possible reasons for policy ineffectiveness.
Impact of BCBV policy on number of prescriptions
The study results indicated a pre-policy increase in the
trend of the monthly number of prescription of ACEIs,
ARBs and CCBs, but a declining trend in those of di-
uretics, BBs and “Others”. The observed reduction in the
trends of the last three groups could be related to their
decreased roles in treating HT following the new NICE
guidelines for treating HT [61] which specifically altered
BBs’ place in therapy from first line treatment to fourth
line of treatment and preferred CCBs over diuretics.
This observed prescribing patterns were consistent with
findings from another study [8] which found an increase
in the prescribing of ACEIs, ARBs, and CCBs; while a
reduction in prescribing of diuretics and BBs in patients
with primary hypertension.
The reduction in post-policy adjusted number of pre-
scriptions for all antihypertensive classes implies that
some systematic factors, other than the BCBV policy
may have contributed to the observed overall reduction.
This hypothesis is considered plausible since the BCBV
prescribing policy did not intend to affect the utilisation
of ACEIs or ARBs, nor the utilisation of other antihyper-
tensive classes, but instead it focused on the proportion
of ACEIs vs. ARBs and encouraged GPs to prescribe
cheaper, generic ACEIs, instead of expensive patented
ARBs only if they made a decision to prescribe a drug
that affects RAS.
Furthermore, one possible factor for the observed
post-policy reduction in the prescribing trends of antihy-
pertensive drugs could be an increase in hypertension
diagnosis and registration after the introduction of QoF
in April 2004, which incentivised GPs to produce a
hypertension registry; hence, hypertension prevalence
and antihypertensive drug prescriptions started to rise
until it reached a plateau after years of the program
introduction. The QoF-induced increase in hypertension
registration reflected clearly on the annual increase of
hypertension prevalence in the UK by about 2.8 %, from
12 % in 2005 to 13.4 % in 2009, in contrast to the 0.75 %
increase from 13.4 % in 2009 to 13.6 % in 2011 [62].
The impact of the launch of generic ACEIs/ARBs items on
cost
This study found a 0.3 % decline in total ACEIs/ARBs
cost during the study period, despite a 7.0 % increase in
the adjusted total number of ACEIs/ARBs prescriptions.
Although the adjusted number of prescriptions increased
for both ACEIs (4.8 %) and ARBs (2.2 %), the cost impli-
cations were different. There was a 28.1 % decrease and
15.7 % increase of ACEIs and ARBs costs, respectively,
largely attributable to the launch of generic perindopril
and losartan in October 2007 and July 2010, respectively.
Furthermore, the continuous decline in the cost of other
generic ACEIs and losartan over time, prompted by the
introduction of the ‘M’ (Manufacturer) and ‘W’ (Whole-
saler) scheme in April 2005 [23], which aimed to in-
crease the transparency in manufacturing and pricing of
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generics as well as any discounts offered to pharmacists
by generic manufacturers, could also have contributed
to the reduction in ACEIs/ARBs cost.
Impact of generic ARBs on BCBV induced cost saving
Since ACEIs have started to almost lose their cost ad-
vantage over ARBs, driven by the availability of more
low cost generic ARBs, it has been argued that ARBs
should replace ACEIs as the first line therapy for hyper-
tension treatment [63], which may indirectly suggest no
further requirement for considering the BCBV indicator.
However, this theoretical argument may not be trans-
lated into action in real life with NICE continuing to ad-
vocate both ACEIs and low cost ARBs as a first line
medical treatment for hypertension.
Analysis of the England PCA data from March 2012
and June 2014 indicated only a small increase in losartan
utilisation (8.9 % absolute increases over 27 month
period), from 36.8 % of all ARBs items in March 2012 to
45.7 % in June 2014. Despite the fact that generic losar-
tan had been listed in the Drug Tariff since July 2010, it
is not surprising to see such a slow increase in losartan
utilisation given the absence of national initiatives to im-
prove ARBs prescribing efficiency as observed in Scotland
[10], and NHS Bury in England until the intigation of mul-
tiple initiatives [59], apart from NICE and others advocat-
ing the prescribing of low cost ARBs alongside ACEIs
before patented ARBs.
A classic case study conducted in NHS Bury in England
[59] found that a combination of education, prescribing
targets and financial incentives, implemented locally in
March 2011 successfully increased losartan utilisation
from 26 % of all ARBs in February 2011 to 65 % in Octo-
ber 2011; this again concluded that multiple initiatives
were required to alter GPs’ prescribing behaviour in order
to improve ARBs prescribing efficiency. Accordingly, due
to the current lack of national multiple initiatives in the
UK, it would be unlikely that losartan utilisation and ARBs
prescribing efficiency would be improved further until
more ARBs lose their patents, This would support why
achieving the proposed BCBV target of 80 % ACEIs could
still achieve potential cost-savings in the short term, even
after years of losing the cost differential between ACEIs
and ARBs.
Nevertheless, the importance of considering the effi-
cient prescribing of RAS drugs in the UK, despite the
availability of low cost generic ARBs, has been empha-
sised by retaining RAS drugs as one of the key thera-
peutic topics for 2015 to support the QIPP framework
[64], as it is not known how fast or far the price of vari-
ous generic ARBs would fall after they came off patent
and it may take probably some years before several
ARBs become available at similar costs to the current
generic ACEIs costs [65]. Indeed, the latter fact can be
clearly observed if we compared the monthly cost of the
typical maintenance dose of the most commonly pre-
scribed ACEIs ramipril to that of generic ARBs [66]. For
example, even after more than four years of its launch as
generic in July 2010, the cost of 28-day treatment of
losartan (100 mg) is still about 14 % higher than that of
ramipril (10 mg) (GB£1.12 vs.GB£1.27). Likewise, the
cost of 28-day candesartan (16 mg), which became off
patent in April 2012, is about 75.9 % higher in compari-
son to ramipril (GB£1.12 vs.GB £1.97) despite more than
two years since its availability as generic.
Implications of the study
The rationale for the BCBV policy was to ensure effi-
cient use of healthcare resources without affecting the
quality of care [29]. This study found that the policy has
no impact on the number and cost of ACEIs/ARBs pre-
scriptions, despite a small impact on ACEIs prescrip-
tions as an overall proportion of RAS drugs. However,
the opportunity of a potential saving is still possible via
enhancement of efficient ACEIs/ARBs prescribing in
NHS primary care practices, even after narrowing the
cost differential between ACEIs and ARBs. These results
suggest the ongoing necessity for reinforcing the BCBV
indicator through the introduction of national and local
measures to enhance its implementation and uptake.
Nevertheless, the opportunity cost of introducing these
measures must also be considered alongside those
required for other high priority areas for efficiency
improvement.
To appropriately reinforce the policy, reasons under-
pinning such failure need further exploration to develop
initiatives to improve the policy effectiveness, building
on existing experience from other European countries,
such as qualitative research to explore physicians’ per-
ceptions of the BCBV policy and the possible causes for
BCBV failure.
Strengths and limitations
To our knowledge, this is the first study to quantify and
evaluate the impact of the BCBV policy on ACEIs/ARBs
utilisation, using a quasi-experimental design on a large,
representative, and high quality dataset. The inter-
rupted segmented regression analysis ensured that
post-intervention changes were not solely a continu-
ation of the long-term trend, as the analysis controlled
for existing, pre-intervention trend [35]. In addition,
the findings of this study were consistent with the ana-
lysis results from another dataset, indicating the expli-
citly of study design and methodology, with the results
are reflective to the national figures.
However, in this secondary data analysis, it was not
possible to determine whether the prescribed drugs were
purely prescribed for hypertension or for other indications
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such as heart failure, which may overestimate the observed
antihypertensive drug utilisation quantity. Although it was
not possible to identify an area free of policy as a reference
group to separate the true policy impact from other pol-
icies, by adopting the alternative approach of using other
antihypertensive drugs as reference groups and considering
the impact for the potential confounders (launch of generic
losartan and generic perindopril), it possibly allowed the es-
timation of the true intervention effect.
Using 2012 price unit instead of the current up to date
price might have biased the cost-saving impact of the
BCBV indicator as the current prices, especially those of
ARBs, might have been lowered following the increasing
availability of ARBs as generics as well as potentially
lowering prices of existing generic ARBs. However, using
June 2014 dispensing data for estimating the cost-saving
impact of the BCBV indicator whilst accounting for
availability of several generic ARBs would have poten-
tially minimised that bias and provided an approximate
picture of the actual impact of BCBV. Finally, we ac-
knowledge that we did not undertake simultaneous
qualitative research among PCTs to ascertain what pos-
sible explanation there could be for no appreciable dif-
ference in the prescribing of ACEIs vs. ARBs despite
potentially appreciable cost savings. However, this will
be included into future research.
Conclusions
The BCBV policy did not change the overall ACEIs/
ARBs utilisation patterns in patients with primary hyper-
tension. Although the BCBV policy was associated with
a small, significant increase in ACEIs prescription pro-
portion, there was no beneficial cost consequence. Inten-
sive and specific measures would be required to enhance
the policy implementation and uptake, given the existing
opportunity for potential saving by further improving
the efficient prescribing of ACEIs/ARBs despite the
availability of low cost generic ARBs. However, this must
be balanced against other priority areas for improving
prescribing quality and efficiency. This study represents
a case study of failed and ineffective policy promoted
probably by its poor implementation. This could be a key
learning point for other healthcare authorities to empha-
sise requirements for effective implementation strategies
as well as the principle policy itself. Further research is
needed to explore the potential factors underpinning the
policy ineffectiveness, and identify the most effective strat-
egies to improve future policy effectiveness.
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